Boehringer Ingelheim and Sweden-based Salipro Biotech have entered a research and licence agreement to expedite the ...

Salipro Biotech has signed a research and license agreement with Boehringer Ingelheim to accelerate the development of multiple drug targets.

STOCKHOLM, March 13, 2025 (GLOBE NEWSWIRE) -- Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license ...

Sotio Biotech is pushing deeper into bispecific antibody-drug conjugates (ADC), taking up its option to use Synaffix’s technology in two candidates. The Czech biotech disclosed the update on the same ...

Boehringer Ingelheim (BI) and Salipro Biotech have entered into a partnership aimed at accelerating the development of ...

STOCKHOLM, March 13, 2025 (GLOBE NEWSWIRE) -- Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, today announced a research and license ...

Boehringer Ingelheim and Sweden-based Salipro Biotech have entered a research and licence agreement to expedite the development of several drug targets. The partnership is set to progress the ...

Salipro Biotech AB is a privately held biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics. The company is headquartered in Stockholm, ...

(MENAFN- GlobeNewsWire - Nasdaq) The collaboration combines Salipro Biotech's unique expertise and its Salipro® platform technology to stabilise challenging drug targets from Boehringer Ingelheim ...